{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:11:34Z","timestamp":1783627894246,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100165","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T10:06:43Z","timestamp":1756116403000},"page":"100165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Final safety and efficacy results from a phase 1\/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4620","authenticated-orcid":false,"given":"Abdulraheem","family":"Yacoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-8668","authenticated-orcid":false,"given":"Minakshi","family":"Taparia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq I.","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2025.100165_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100165_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100165_bib3","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: single-center experience","volume":"128","author":"Masarova","year":"2022","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.bneo.2025.100165_bib4","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bneo.2025.100165_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.bneo.2025.100165_bib6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2025.100165_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/ejh.13330","article-title":"Survival outcomes in myelofibrosis patients treated with ruxolitinib: a population-based cohort study in Sweden and Norway","volume":"103","author":"Schain","year":"2019","journal-title":"Eur J Haematol"},{"issue":"suppl_1","key":"10.1016\/j.bneo.2025.100165_bib8","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood-2019-122904","article-title":"Overall survival in patients with myelofibrosis who have discontinued ruxolitinib: a literature review","volume":"134","author":"Tang","year":"2019","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.bneo.2025.100165_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/01.HS9.0000564104.83392.dc","article-title":"PS1460 long-term follow up of JAK inhibitor (JAKi) treated patients with myelofibrosis: impact of molecular enhanced integrated scoring systems and type of JAKi therapy failure on survival","volume":"3","author":"Mcnamara","year":"2019","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.bneo.2025.100165_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100165_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ajh.26889","article-title":"Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms","volume":"98","author":"Ivanov","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100165_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.hemonc.2019.01.001","article-title":"Phenotypic characterization of malignant progenitor cells in patients with idiopathic myelofibrosis","volume":"12","author":"Bao","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"9","key":"10.1016\/j.bneo.2025.100165_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/cancers11091358","article-title":"CD123 as a therapeutic target in the treatment of hematological malignancies","volume":"11","author":"Testa","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bneo.2025.100165_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2025.100165_bib15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bneo.2025.100165_bib16","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1182\/blood.V124.21.5577.5577","article-title":"Expression of CD123 (IL-3R-alpha), a therapeutic target of SL-401, on myeloproliferative neoplasms","volume":"124","author":"Lasho","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100165_bib17","series-title":"Tagraxofusp exhibits antitumoral activity in preclinical models of myelofibrosis and enhances antileukemic activity of JAK inhibitors","author":"Nicolis di Robilant","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100165_bib18","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1182\/blood-2023-178864","article-title":"Tagraxofusp shows promising anti-tumoral efficacy in preclinical in vitro models of myelofibrosis, both as a single agent and in combination with Janus kinase inhibitors","volume":"142","author":"Iannitto","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100165_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100115","article-title":"Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1\/2 study","volume":"2","author":"Patnaik","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100165_bib20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2025.100165_bib21","series-title":"Elzonris (tagraxofusp-erzs) injection. Prescribing information","year":"2023"},{"issue":"8","key":"10.1016\/j.bneo.2025.100165_bib22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100165_bib23","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100165_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-022-00713-6","article-title":"Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis","volume":"12","author":"Coltro","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.bneo.2025.100165_bib25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100165_bib26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100165_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"issue":"26","key":"10.1016\/j.bneo.2025.100165_bib28","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100165_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00277-021-04683-w","article-title":"Favorable overall survival with imetelstat in relapsed\/refractory myelofibrosis patients compared with real-world data","volume":"101","author":"Kuykendall","year":"2022","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100165_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-135872","article-title":"Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor na\u00efve and previously JAK Inhibitor treated intermediate\/high risk myelofibrosis patients","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2025.100165_bib31","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bneo.2025.100165_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.15061","article-title":"Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100165_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100165_bib34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:41:05Z","timestamp":1764121265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025001001"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100165","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final safety and efficacy results from a phase 1\/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100115","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100165"}}